A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC — Stella

Recruiting

Back to Prostate Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Key details

Phase

Early testing

Sponsor

M.D. Anderson Cancer Center

Collaborators

Regeneron Pharmaceuticals

Enrollment target

~60 participants

Started

July 2025

Primary completion

May 2027

Age range

18 Years and older

Sex

Male only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov